百利天恒(688506) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 252,011.33 million, a decrease of 56.72% compared to the previous year[3] - Net profit attributable to shareholders of the parent company was CNY -105,065.33 million, a decline of 128.34% year-over-year[4] - The basic earnings per share were CNY -2.54, a decrease of 127.46% compared to the previous year[3] - The weighted average return on net assets decreased by 209.33 percentage points to -24.47%[3] Assets and Equity - The company reported a total asset increase of 60.40%, reaching CNY 1,144,832.11 million at the end of the reporting period[4] - The equity attributable to shareholders of the parent company increased by 70.46%, amounting to CNY 662,399.74 million[4] - The increase in total assets and equity was primarily due to funds raised from a specific issuance of A-shares[6] Research and Development - The company has 17 innovative drugs in clinical trials, with 6 in global trials and over 100 ongoing clinical trials worldwide[5] - The core product, iza-bren, has received acceptance for its NDA application and is included in the priority review process by the National Medical Products Administration[5] - The company experienced a significant increase in R&D investment, contributing to the decline in profits[6]